Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Stem Cell Therapy
IOM’s Shapiro Wants to See More Changes from California Stem Cell Agency
Posted: February 3, 2013 at 8:10 am
Additional mainstream media news
coverage surfaced last Friday involving the California stem cell
agency's response to the blue-ribbon report from the Institute of
Medicine(IOM), whose concerns about the agency ranged from conflicts of interest to grant
appeals by rejected researchers.
One of the more interesting pieces was
done by Stephanie O'Neill of Los Angeles radio station KPCC. To her
credit, she contacted the chairman of the IOM panel, Harold Shapiro,
for his fresh take on what the stem cell agency's board did on
Wednesday.
done by Stephanie O'Neill of Los Angeles radio station KPCC. To her
credit, she contacted the chairman of the IOM panel, Harold Shapiro,
for his fresh take on what the stem cell agency's board did on
Wednesday.
His comments were somewhat different
than those read Wednesday at the CIRM board meeting. On Friday, Shapiro was quoted as
saying the board action was “an important first step forward,”
but he added a caveat. O'Neill wrote,
than those read Wednesday at the CIRM board meeting. On Friday, Shapiro was quoted as
saying the board action was “an important first step forward,”
but he added a caveat. O'Neill wrote,
“'I’m encouraged by this,' Shapiro
told KPCC. 'Presumably in the future they’ll take other steps. But
these are steps they could take without any legislative approval and
…I think it does respond in a pretty significant way to the spirit
of the report.'
“But Shapiro expressed concern that
the agency is making only 'small moves' to address a recommendation
that CIRM separate operations from oversight. Currently, the ICOC
functions 'both as an executor and as an overseer—competing duties
that compromise the ICOC’s critical role of providing independent
oversight and strategic direction,' according to the December IOM
report.
“'But I do understand… that
would be a move that they would have to take over time so we’ll
have to wait and see,' Shapiro said.
“Thomas agreed and said that while
CIRMs recommendations more clearly define the roles of chairman and
president, more refinements will be likely over time.”
From the Los Angeles Times, came a
piece from Eryn Brown. Her article was brief and she referred her
readers to the California Stem Cell Report for details. Her first
paragraph said,
piece from Eryn Brown. Her article was brief and she referred her
readers to the California Stem Cell Report for details. Her first
paragraph said,
“Changes may be on the way at
California’s stem cell funding agency.”
In coverage outside the mainstream media,
the Burrill Report carried an article by Daniel Levine. The Burrill
Report is produced by Burrill & Co., a San Francisco life
sciences financial firm. Levine's straight-forward account was
largely based on the CIRM press release and the IOM report.
the Burrill Report carried an article by Daniel Levine. The Burrill
Report is produced by Burrill & Co., a San Francisco life
sciences financial firm. Levine's straight-forward account was
largely based on the CIRM press release and the IOM report.
Two bloggers surfaced with some
coverage. UC Davis stem cell researcher Paul Knoepfler, who is a CIRM
grantee, called the Thomas plan a “bold one-year experiment” and
“biggest development for CIRM in many years.” Knoepfler said,
coverage. UC Davis stem cell researcher Paul Knoepfler, who is a CIRM
grantee, called the Thomas plan a “bold one-year experiment” and
“biggest development for CIRM in many years.” Knoepfler said,
“I’m still not sure I’m a fan of
all of the proposed changes, but I would say the plan is bold and
creative.”
On livingbiology.com, an unidentified
CIRM grantee carried a few brief items live from the meeting.
CIRM grantee carried a few brief items live from the meeting.
Posted in Stem Cells, Stem Cell Therapy
Comments Off on IOM’s Shapiro Wants to See More Changes from California Stem Cell Agency
Norman's Stemlogix Stem Cell Therapy Treatment at County Animal Clinic – Video
Posted: February 2, 2013 at 10:42 pm
Norman #39;s Stemlogix Stem Cell Therapy Treatment at County Animal Clinic
This is a video of live news coverage courtesy of WHIO TV of Dayton, Ohio. NORMAN A 5 YEAR OLD BLACK LAB SUFFERED A STROKE, AND WAS BROUGHT TO THE COUNTY ANIMAL CLINIC FOR A STEMLOGIX STEM CELL TREATMENT. THIS CREATED QUITE A BIT OF INTEREST FROM THE NEWS MEDIA. NOW AFTER 2 INFUSIONS NORMAN IS ALREADY SHOWING SIGNS OF RECOVERY.
By: StemLogixLLC
Originally posted here:
Norman's Stemlogix Stem Cell Therapy Treatment at County Animal Clinic - Video
Posted in Stem Cell Therapy
Comments Off on Norman's Stemlogix Stem Cell Therapy Treatment at County Animal Clinic – Video
MSI Pre-Stem Cell Therapy – Video
Posted: February 2, 2013 at 5:46 pm
MSI Pre-Stem Cell Therapy
Buyer came to VOSM in 2009 with medial shoulder instability. This is what the damaged tissues inside his shoulder looked like at that point, prior to stem cell injections and radiofrequency treatments.
By: VetSportsMedicine
Continued here:
MSI Pre-Stem Cell Therapy - Video
Posted in Stem Cell Therapy
Comments Off on MSI Pre-Stem Cell Therapy – Video
Dr.Omar Gonzalez Stem Cell Therapy Method – Video
Posted: February 2, 2013 at 5:46 pm
Dr.Omar Gonzalez Stem Cell Therapy Method
New Project 75
By: OmarGonzalezMD
View post:
Dr.Omar Gonzalez Stem Cell Therapy Method - Video
Posted in Stem Cell Therapy
Comments Off on Dr.Omar Gonzalez Stem Cell Therapy Method – Video
Angie the Chimp Receives Stemlogix Stem Cell Therapy – Video
Posted: February 2, 2013 at 5:45 pm
Angie the Chimp Receives Stemlogix Stem Cell Therapy
Angie the chimp received Stemlogix stem cell therapy to treat her torn ACL. Video is courtesy of WPTV - read the full article: Chimp with torn ACL receives stem cell treatment at http://www.wptv.com
By: StemLogixLLC
Excerpt from:
Angie the Chimp Receives Stemlogix Stem Cell Therapy - Video
Posted in Stem Cell Therapy
Comments Off on Angie the Chimp Receives Stemlogix Stem Cell Therapy – Video
Sacramento Bee: Stem Cell Agency Falling Short on IOM Recommendations
Posted: February 1, 2013 at 1:28 pm
It's exceedingly rare when the
California stem cell agency makes the front page of any newspaper.
So it is worthy of note that The
Sacramento Bee this morning carried a lengthy piece on its page one
about the agency and its response to the blue-ribbon Institute of
Medicine (IOM) report.
Sacramento Bee this morning carried a lengthy piece on its page one
about the agency and its response to the blue-ribbon Institute of
Medicine (IOM) report.
The headline said,
“Analyst: Stem
cell agency reforms fall short.”
The analyst is the Institute of
Medicine, more specifically Harold Shapiro, chairman of the panel that
studied California's $3 billion research effort for 17 months at
a cost of $700,000 to the agency.
Medicine, more specifically Harold Shapiro, chairman of the panel that
studied California's $3 billion research effort for 17 months at
a cost of $700,000 to the agency.
Bee reporter Cynthia Craft wrote that
Shapiro said the stem cell agency is “falling short” in its
response to the IOM recommendation.
Shapiro said the stem cell agency is “falling short” in its
response to the IOM recommendation.
Craft wrote,
"'There certainly is a gap between
what we recommended and what they responded with,' said Shapiro,
president emeritus at Princeton
University. ' I wish they had moved closer to our
recommendations.'"
Craft said the IOM made sweeping recommendations “emphasizing the need for new blood on a governing
board that has been plagued by the appearance of conflicts of
interest, cronyism and sluggishness in getting stem-cell products to
market.”
board that has been plagued by the appearance of conflicts of
interest, cronyism and sluggishness in getting stem-cell products to
market.”
Craft also interviewed Jonathan
Thomas, chairman of the stem cell agency, who said some of the IOM
recommendations would take legislative action. But Thomas said that
was “out of the question.”
Thomas, chairman of the stem cell agency, who said some of the IOM
recommendations would take legislative action. But Thomas said that
was “out of the question.”
Craft wrote,
“The process would take years, he
said. The first opportunity to get on the ballot, for instance, would
be in the fall of 2014.”
The agency will run out of cash for new
grants in less than four years.
grants in less than four years.
Craft's story was the first major news
article in years about the agency in the Bee, the only daily
newspaper in the state's capital. She reviewed a bit of the history
of the agency and concerns about conflicts of interest. She
concluded,
article in years about the agency in the Bee, the only daily
newspaper in the state's capital. She reviewed a bit of the history
of the agency and concerns about conflicts of interest. She
concluded,
“Shapiro said he stands firmly behind
his committee's report.
"'I think our recommendations sit
together and interrelate to each other well – and should have been
moved along as quickly as possible,' Shapiro said.
"'It might have been helpful if
they indicated to us what they were willing to do and what they
weren't,' he said."
Posted in Stem Cells, Stem Cell Therapy
Comments Off on Sacramento Bee: Stem Cell Agency Falling Short on IOM Recommendations
Beauty Innovation: Young-looking skin with stem cell therapy
Posted: February 1, 2013 at 10:44 am
Admit it or not, as you age your skin starts showing signs that you would rather hide. Spots, wrinkles, and even crow's feet are just some of those signs that you would camouflage with makeup and skin creams to make them disappear-temporarily. But fear not, for beauty experts have discovered that stem cell treatment can also help in maintaining youthful skin.
According to Ma Fe Doria, a skin care expert, stem cell therapy is an intervention strategy that introduces new adult stem cells into damaged tissue in order to treat disease or injury. As many may be aware, the most popular stem cell treatment is in Germany, where lots of celebrities and personalities (i.e. politicians) have flown to have stem cell injections for their ailments, using cells mostly harvested from the sheep. According to those who have undergone the procedure, the treatments have improved their body and the pains they've experienced have disappeared.
Today, many medical researchers continue to do experiments to determine if stem cell can help in curing various types of ailments from cancer to diabetes, which doctors have said may not be far behind. Aside from its healing benefits, stem cell is now being used by the beauty industry. Many cosmetic and beauty centers have started offering stem cell injections for the face, which is said to regenerate the skin where the cells are injected. While some continue to use sheep cells, plant and fat stem cells are now becoming the popular alternatives, with the fat stem cells being used to heal wounds, improve scars, and rejuvenate the skin.
But stem cell treatment is not cheap. Those who can afford it need to fly out of the country to avail of the treatment. Realizing the need in the market, Flawless Facial Center partnered with a local industry leader to produce Flawless' Stem Cell line, which uses the potent power of plant stem cells. Dubbed as the "superfood for the skin," Flawless' Stem Cell line is the epitome of skin nutrition.
"This new range of products allowed us to mark several milestones not just for Flawless but for the local beauty industry. Once again, we have taken something that, for the longest time, has remained exclusive to celebrities and other influential people, and made it affordable for the regular Juan and Juana," says Flawless ceo Ruby Sy.
For P2,500, the line includes a cleanser, day cream, and night serum. Flawless' Stem Cell line utilizes the plant stem cell technology to achieve the skin's youthful appearance by protecting it against oxidative stress and boosting the skin's repair and rejuvenation systems. "Times have really changed. No thanks to free radicals that are present in almost everything around us-from the food we eat to the air we breathe-people today age so much faster. This is especially true for people who like to spend late nights partying or spend too much time in front of the [TV/computer] monitor. Various studies have proven time and again the harmful effects such activities have on our skin," Sy said.
But with Flawless' latest baby, you can say goodbye to those ugly marks on your face. The Stem Cell line promises to solve all these, and more, by providing your skin with the right amount of nutrition and protection. Indeed, youthful glow is not only safe and available in a bottle, it's also now within reach of your pocket.
Go to http://www.flawless.com.ph for
store locations
Follow this link:
Beauty Innovation: Young-looking skin with stem cell therapy
Posted in Cell Therapy, Stem Cell Therapy
Comments Off on Beauty Innovation: Young-looking skin with stem cell therapy
Hyping the Economic Impact of the California Stem Cell Agency
Posted: January 31, 2013 at 9:03 pm
The $3 billion California stem cell agency today served up a warmed-over version of a study that would have the
public believe that the research program has had a major economic
impact on the state.
The latest study was prepared last
August by a firm that was hired under an RFP in 2010 that said it must execute "a vibrant and aggressive strategy to support the goals and initiatives of CIRM.”
August by a firm that was hired under an RFP in 2010 that said it must execute "a vibrant and aggressive strategy to support the goals and initiatives of CIRM.”
The agency paid $300,000 for the
original study but contends the report is “independent” of CIRM.
original study but contends the report is “independent” of CIRM.
According to the CIRM press release
today, the latest version of the study by Jose Alberro of the
Berkeley Research Group claims creation of 38,000 “job years” and
$286 million in “new tax revenue” from the award of $1.5 billion. Those awards actually cost something in the neighborhood of $3 billion, given that state taxpayers must pay interest the borrowed funds that finance the agency.
today, the latest version of the study by Jose Alberro of the
Berkeley Research Group claims creation of 38,000 “job years” and
$286 million in “new tax revenue” from the award of $1.5 billion. Those awards actually cost something in the neighborhood of $3 billion, given that state taxpayers must pay interest the borrowed funds that finance the agency.
The Institute of Medicine's recent
blue-ribbon report on the stem cell agency carried remarkably different
information than the economic figures reported today. The institute's study was also financed by CIRM but at a cost of
$700,000. The report said,
blue-ribbon report on the stem cell agency carried remarkably different
information than the economic figures reported today. The institute's study was also financed by CIRM but at a cost of
$700,000. The report said,
“In the short term, CIRM’s
expenditures are supporting approximately 3,400 jobs and their
innovative efforts have also attracted substantial additional private
and institutional resources to this research arena in California
CIRM’s long-term impact on such critical aspects of the California
economy as state tax revenues and health care costs beyond the
shorter-term and temporary impact of its direct expenditures cannot
be reliably estimated at this point in CIRM’s history."
Here is what the California Stem Cell Report wrote in 2011 when the first study was released:
“No doubt exists that the stem cell
spending has had a beneficial economic impact. But whether it has had
a 'significant' impact on the California economy is in the eye of the
beholder. The state's economy runs to something like $1.7 trillion a
year. If California were a nation, it would rank among one of the
larger economies in the world. The workforce totals around 18
million, making 25,000 jobs statistically less than a hiccup. Keep in
mind as well that CIRM, until 2009, paid the interest on its
borrowing with more borrowed funds, all of which adds to the total
cost of the borrowing, which is about $3 billion on top of the $3
billion CIRM is handing out.”
By ballyhooing economic impact reports
the stem cell agency would seem to be inviting assessment of its
efforts as an industrial development enterprise, which involve
criteria significantly different than that of a research enterprise.
A few years ago, we asked the agency's then Chairman Robert Klein
whether he wanted to have CIRM assessed as industrial development
effort. His quick response was a very emphatic no. Klein nonetheless
frequently touted the figures produced under the contract with the
agency.
the stem cell agency would seem to be inviting assessment of its
efforts as an industrial development enterprise, which involve
criteria significantly different than that of a research enterprise.
A few years ago, we asked the agency's then Chairman Robert Klein
whether he wanted to have CIRM assessed as industrial development
effort. His quick response was a very emphatic no. Klein nonetheless
frequently touted the figures produced under the contract with the
agency.
The latest figures are undoubtedly
likely to be cited as the agency begins a road trip around the state
to meet with newspaper editorial boards to trumpet CIRM's reponse to
the Institute of Medicine study.
likely to be cited as the agency begins a road trip around the state
to meet with newspaper editorial boards to trumpet CIRM's reponse to
the Institute of Medicine study.
See below for a full copy of the
report. We have asked CIRM for a copy of the contract with the group
that prepared it. We will carry it when we receive it.
report. We have asked CIRM for a copy of the contract with the group
that prepared it. We will carry it when we receive it.
Posted in Stem Cells, Stem Cell Therapy
Comments Off on Hyping the Economic Impact of the California Stem Cell Agency
Los Angeles Times Columnist: Stem Cell Agency Still Saddled with Conflict of Interest Problems
Posted: January 30, 2013 at 12:49 pm
The governing board of the $3 billion
California stem cell agency will remain dominated by “special
interests” even with the adoption of a plan last week responding to
the far-reaching recommendations of a blue-ribbon Institute of
Medicine (IOM) study, a columnist for the Los Angeles Times said today.
Michael Hiltzik, Pulitzer Prize winning
writer and author, wrote that IOM study showed the agency “the path
to cleansing itself of its aura of connivance and influence trading.
That the board can't even bring itself to place the proposals before
the voters or their elected representatives only shows how much money
it's willing to waste to keep living in its own little world.”
writer and author, wrote that IOM study showed the agency “the path
to cleansing itself of its aura of connivance and influence trading.
That the board can't even bring itself to place the proposals before
the voters or their elected representatives only shows how much money
it's willing to waste to keep living in its own little world.”
Hiltzik's column in California'slargest circulation newspaper included fresh comments from both
Harold Shapiro, who chaired 17-month IOM study, which was
commissioned by CIRM, and Jonathan Thomas, the chairman of CIRM and
who drew up the response.
Harold Shapiro, who chaired 17-month IOM study, which was
commissioned by CIRM, and Jonathan Thomas, the chairman of CIRM and
who drew up the response.
Hiltzik wrote that the study “concluded
that the CIRM board members were saddled with 'almost unavoidable
conflicts of interest, whether actual or perceived.'” He continued,
that the CIRM board members were saddled with 'almost unavoidable
conflicts of interest, whether actual or perceived.'” He continued,
“That's because by law, 23 of the 29
members must be representatives of California institutions eligible
for CIRM grants or of disease advocacy groups with their own interest
in steering money toward their particular concerns.
“As a remedy, the panel proposed
eliminating some board slots reserved for grant-receiving
institutions by Proposition
71, the 2004 initiative that created the agency. The idea
was to fill those slots with truly independent members free of any
stake in CIRM funding, even indirectly.”
Hiltzik wrote,
"Thomas told me his proposal dealt
with even perceived conflicts of interest on the board in such
"definitive fashion" that it won't be necessary to bother
the Legislature, much less the voters, with such big changes as
remaking the board with a majority of independent members. He pointed
out, not without some pride, that one board member called his
proposed changes 'draconian.'"
Hiltzik had some praise for Thomas.
“Let's stipulate that Thomas has, in
CIRM terms, moved a mountain by jostling the board even this far.
Since its inception, the board has set records for arrogance. That's
a direct legacy from Proposition 71, which exempted the stem cell
program, uniquely among California government bodies, from any
practical oversight by the Legislature or elected officials.”
The Times columnist continued,
“Shapiro told me from his Princeton
office that Thomas' proposals were 'a significant step in the right
direction, which at least indicates that they haven't ignored the
report.' But he doesn't share Thomas' view that voluntary recusals
solve the conflict of interest problem. That can be done, Shapiro
said, only by replacing stake-holding board members with
independents.
"'The more you can reduce the
inherent conflicts, the better off everyone is going to be,' he said.
The board will 'have to go further over time, in my view.'"
Hiltzik wrote,
“The Shapiro panel said it didn't
find any instances of inappropriate behavior by board members or
specific conflicts, but there are two reasons for that: It didn't
search for any, and Proposition 71 defined certain conflicts out of
existence. The measure states that it's no conflict for a board
member to also be an officer of an academic institution or private
corporation that might be applying for grants.“One of the CIRM board's enduring
self-delusions is that its conflicts of interest are purely a matter
of 'perception.' But there have been documented instances
of favoritism shown to well-connected grant or loan applicants, and
at least one overt attempt by a board member to overturn a rejection
of his institution's project. So much of the board's discussion takes
place behind closed doors or informally that the opportunities for
mutual back scratching are incalculable.
“Thomas' 'draconian' proposals won't
change this state of affairs. Special interests will still dominate
the board. Will barring 13 members from voting on grants while giving
them full rein to participate in discussions really eradicate even
the perception of conflicts? You'd have to be terminally naive to
think so.”
Posted in Stem Cells, Stem Cell Therapy
Comments Off on Los Angeles Times Columnist: Stem Cell Agency Still Saddled with Conflict of Interest Problems
Stem Cell Agency Plan Falls Far Short of Solving IOM Concerns
Posted: January 30, 2013 at 2:18 am
Posted in Stem Cells, Stem Cell Therapy
Comments Off on Stem Cell Agency Plan Falls Far Short of Solving IOM Concerns